Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Yabao Pharmaceutical
Yabao Pharmaceutical
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
Yabao Pharmaceuticals and Salus Pharma announce strategic partnership for generic drugs
Yabao Pharmaceuticals is a leading Chinese pharmaceutical company with fully integrated development, manufacturing and commercialisation capabilities
Research & Development
Yabao and Sciecure Pharma to develop, manufacture and commercialise generics for US and China
No financial terms are released
Research & Development
Yabao Pharmaceuticals enters second collaboration with Eli Lilly
To develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule which has completed pre-clinical development
Research & Development
Yabao Pharmaceuticals and University of South Australia announce new drug discovery laboratory
New collaboration will focus on the development of new treatments for cancer
Subscribe now